Lipocine (LPCN) Revenue & Revenue Breakdown
Lipocine Revenue Highlights
Latest Revenue (Y)
$109.99K
Latest Revenue (Q)
$89.56K
Main Segment (Y)
License
Lipocine Revenue by Period
Lipocine Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $109.99K | -78.00% |
| 2022-12-31 | $500.00K | -96.90% |
| 2021-12-31 | $16.14M | 100.00% |
| 2020-12-31 | - | -100.00% |
| 2019-12-31 | $164.99K | -61.45% |
| 2018-12-31 | $428.03K | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2011-12-31 | - | - |
Lipocine generated $109.99K in revenue during NA 2023, up -78.00% compared to the previous quarter, and up 25.70% compared to the same period a year ago.
Lipocine Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $89.56K | -98.82% |
| 2024-03-31 | $7.62M | 13750.16% |
| 2023-12-31 | $55.00K | -101.76% |
| 2023-09-30 | $-3.12M | 100.00% |
| 2023-06-30 | - | -100.00% |
| 2023-03-31 | $54.99K | -99.42% |
| 2022-12-31 | $9.50M | 100.00% |
| 2022-09-30 | - | -100.00% |
| 2022-06-30 | $500.00K | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $16.09M | 29150.18% |
| 2021-09-30 | $54.99K | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | -100.00% |
| 2019-12-31 | $164.83M | 99800.00% |
| 2019-09-30 | $164.99K | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | -100.00% |
| 2018-12-31 | $235.39M | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | -100.00% |
| 2018-03-31 | $428.03K | -97.68% |
| 2017-12-31 | $18.47M | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | -100.00% |
| 2016-12-31 | $13.50M | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2012-03-31 | - | - |
Lipocine generated $89.56K in revenue during Q2 2024, up -98.82% compared to the previous quarter, and up 162.88% compared to the same period a year ago.
Lipocine Revenue Breakdown
Lipocine Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| License | $109.99K | $500.00K | $11.00M |
| Materials | - | - | $1.04M |
| Minimum guaranteed royalties | - | - | $4.05M |
| Sales-based royalties | - | - | $54.99K |
Lipocine's latest annual revenue breakdown by segment (product or service), as of Dec 23: License (100.00%).
Lipocine Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ARDX | Ardelyx | $124.46M | $73.22M |
| SGTX | Sigilon Therapeutics | $12.94M | $5.90M |
| UNCY | Unicycive Therapeutics | $675.00K | - |
| LPCN | Lipocine | $109.99K | $89.56K |
| CKPT | Checkpoint Therapeutics | $103.00K | $41.00K |
| EYEN | Eyenovia | $3.79K | $4.99K |
| VSTM | Verastem | - | $10.00M |
| AVRO | AVROBIO | - | - |
| MBIO | Mustang Bio | - | - |
| RVPH | Reviva Pharmaceuticals | - | - |
| ZURA | Zura Bio | - | - |
| CGTX | Cognition Therapeutics | - | - |
| ZVSA | ZyVersa Therapeutics | - | - |
| KOD | Kodiak Sciences | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
| RNAZ | TransCode Therapeutics | - | - |
LPCN Revenue FAQ
What is Lipocine’s yearly revenue?
Lipocine's yearly revenue for 2023 was $109.99K, representing a decrease of -78.00% compared to 2022. The company's yearly revenue for 2022 was $500K, representing a decrease of -96.90% compared to 2021. LPCN's yearly revenue for 2021 was $16.14M, representing an increase of 100.00% compared to 2020.
What is Lipocine’s quarterly revenue?
Lipocine's quarterly revenue for Q2 2024 was $89.56K, a -98.82% decrease from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $7.62M, a 13750.16% increase from the previous quarter (Q4 2023), and a 13751.93% increase year-over-year (Q1 2023). LPCN's quarterly revenue for Q4 2023 was $55K, a -101.76% decrease from the previous quarter (Q3 2023), and a -99.42% decrease year-over-year (Q4 2022).
What is Lipocine’s revenue growth rate?
Lipocine's revenue growth rate for the last 3 years (2021-2023) was -99.32%, and for the last 5 years (2019-2023) was -33.34%.
What are Lipocine’s revenue streams?
Lipocine's revenue streams in c 23 are License
What is Lipocine’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Lipocine was License. This segment made a revenue of $109.99K, representing 100.00% of the company's total revenue.